Epigenetic Reader Domain

Tuftelin 1 Facilitates Hepatocellular Carcinoma Progression through Regulation of Lipogenesis and Focal Adhesion Maturation

32 views | Jan 06 2024

The study delineates TUFT1's pivotal role in hepatocellular carcinoma (HCC) progression by elucidating its influence on lipid metabolism, cell proliferation through CREB1 interaction, and invasion via modulation of zyxin expression and recruitment to focal complexes in HCC cells. [Read the Full Post]

CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer

32 views | Dec 24 2023

The study's use of CPI-203, a BRD4 inhibitor, in conjunction with PD-1 antibodies shows promising potential to overcome PD-L1-mediated resistance to immunotherapy in hepatocellular carcinoma. [Read the Full Post]

NHWD-870 protects the kidney from ischemia/reperfusion injury by upregulating the PI3K/AKT signaling pathway (experimental study)

49 views | Dec 23 2023

NHWD-870 exhibits substantial nephroprotective effects by attenuating renal damage through its anti-apoptotic, anti-inflammatory, and antioxidant properties, indicating potential therapeutic promise in managing renal ischemia-reperfusion injury. [Read the Full Post]

Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

24 views | Nov 25 2023

In a phase I trial, the combination therapy of PLX51107 (a bromodomain and extra-terminal domain inhibitor) and azacitidine demonstrated a 22% overall response rate and significant changes in gene and protein expressions, providing modest clinical benefit in heavily pre-treated patients with relapsed/refractory high-risk myelodysplastic syndrome and acute myeloid leukemia. [Read the Full Post]

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis

24 views | Nov 19 2023

The passage discusses how acute treatment with the antiandrogen enzalutamide induces ferroptosis in prostate cancer cells by decreasing glutathione production, increasing lipid peroxidation, and upregulating the cystine transporter gene SLC7A11 through both full-length and variant forms of the androgen receptor, revealing a potential mechanism for therapeutic resistance and identifying a target for intervention. [Read the Full Post]

The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells

0 views | Nov 10 2023

A1874, a novel BRD4-degrading PROTAC, demonstrates potent anti-colon cancer activity through both BRD4-dependent and -independent mechanisms, inhibiting cell growth, inducing apoptosis, and showing efficacy in in vivo models. [Read the Full Post]

Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer

12 views | Nov 03 2023

This study found that the effectiveness of chemotherapy agents varied in platinum-resistant ovarian cancer patients based on tumor characteristics, such as histological type and platinum-free interval, as well as the use of bevacizumab. [Read the Full Post]

Knockdown screening of chromatin binding and regulatory proteins in zebrafish identified Suz12b as a regulator of tfpia and an antithrombotic drug target

82 views | Oct 15 2023

This study identified novel epigenetic regulators of the tfpia gene and demonstrated the potential of UNC6852 as an antithrombotic drug by enhancing tfpia mRNA levels and prolonging the time to occlude the caudal vessel after laser injury in zebrafish larvae and adults. [Read the Full Post]

BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma

51 views | Sep 29 2023

The study revealed that BRD9 plays important roles in colon cancer metabolism and tumor progression, highlighting its potential as a valuable therapeutic target for patients with colon cancer (COAD). [Read the Full Post]

Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction

19 views | Sep 20 2023

NHWD-870, a potent BET inhibitor, shows superior efficacy to current clinical stage inhibitors, suppressing tumor growth by downregulating c-MYC, inhibiting tumor cell proliferation, and blocking TAM proliferation through the suppression of CSF1 expression mediated by BRD4 inhibition and its target HIF1α. [Read the Full Post]